Long-term data presented at ASCO confirm prolonged survival times of patients with acute leukaemia treated with TK cell therapy The use of TK has enabled the execution of haploidentical donor transplants, with an overall survival similar to transplants from fully compatible donors MolMed S.p.A. provided today at the 49th ASCO annual meeting an ... (more)
http://ireport.cnn.com/docs/DOC-985474?ref=feeds%2Flatest
http://ireport.cnn.com/docs/DOC-985474?ref=feeds%2Flatest
No comments:
Post a Comment